Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC

Completed · Phase 2 · Has a placebo group

Conditions studied: Tuberous Sclerosis Complex

In brief

The study intends to show that basimglurant (NOE-101) provides effective seizure control in children, adolescents and young adults with Tuberous Sclerosis Complex (TSC).

Key facts

Study ID
NCT05059327
Run by
Noema Pharma AG
People needed
61
Starts
2022-03-03
Expected to finish
2025-04-28
Last updated by the study team
2025-06-04

Who can join

Age: 5 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.